Phase 1 Open-label Dose Escalation and Expansion Study of ZEN003365 in Subjects With Relapsed or Refractory Lymphoproliferative Malignancies or Acute Myeloid Leukemia
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2016
At a glance
- Drugs ZEN 3365 (Primary)
- Indications Acute myeloid leukaemia; Lymphoproliferative disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Zenith Epigenetics Corp
- 12 Nov 2014 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 02 Oct 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.
- 19 Sep 2014 New trial record